Drugs / RNA-144101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01093170 | Mar 2011 → Sep 2012 | diffuse secondary choroid atrophy | Mark Kleinman | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNA-144101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01093170 ↗ |
| Route | Intravitreal | “Intravitreous administration of RNA-144101” NCT01093170 ↗ |